

Supplementary material

Bandura A, Kurlapski M, Kamińska M, et al. Profound neutropenia related to consolidation durvalumab treatment following concurrent radiochemotherapy in a patient with stage III non–small-cell lung cancer. Pol Arch Intern Med. 2022; 132: 16161. doi:10.20452/pamw.16161

Please note that the journal is not responsible for the scientific accuracy or functionality of any supplementary material submitted by the authors. Any queries (except missing content) should be directed to the corresponding author of the article.

Table S1. Laboratory summary data. Table of complete blood count and administered treatment.

Date	10.09.2018	08.03.2019	05.04.2019	06.05.2019	30.05.2019	11.06.2019	21.06.2019	02.07.2019	05.07.2019	07.07.2019	08.07.2019	21.07.2019	04.11.2019
WBC [$\times 10^9/L$]	3.46	3.42	3.12	2.21	1.85	1.85	2.04	1.49	2.12	2.36	3.60	6.10	4.63
ANC [$\times 10^9/L$]	2.39	1.78	1.53	0.68	0.45	0.39	0.34	0.08	0.04	0.19	1.07	4.00	2.85
PLT [$\times 10^9/L$]	185	194	199	189	167	160	156	111	118	131	143	174	183
HGB [g/dl]	11.5	13.1	12.8	13.0	12.1	12.4	12.0	12.4	11.7	12.0	12.3	12.5	12.7
Treatment	Durvalumab, 19.09.2018 - 21.05.2019 (16 cycles)				Observation			Prednisone 1 mg/kg, antibiotics	Prednisone 1 mg/kg, G-CSF, antibiotics continued			Prednisone tapering, G-CSF stopped	Prednisone stopped